PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Medicine, Department of Metabolism and Experimental Therapeutics, University College London, London, UK.\', \'Department of Endocrinology, OCDEM, University of Oxford, Oxford, UK.\', \'Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK.\', \'Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK.\', \'Department of Diabetes and Endocrinology, University College London Hospital NHS Foundation Trust, London, UK.\', \'Division of Medicine, University College London, London, UK.\', \'Centre for Neuroendocrinology, Royal Free Campus, University College London, London, UK.\', \'First Department of Propaedeutic and Internal Medicine, Laiko University Hospital, National and Kapodistrian University of Athens, Athens, Greece.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1530/EJE-21-0281EJE-21-0281
?:doi
?:hasPublicationType
?:journal
  • European journal of endocrinology
is ?:pmid of
?:pmid
?:pmid
  • 34370712
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.892
?:rankingScore_hIndex
  • 126
is ?:relation_isRelatedTo_publication of
?:title
  • MANAGEMENT OF ENDOCRINE DISEASE: Dysnatraemia in COVID-19: prevalence, prognostic impact, pathophysiology, and management.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all